Related Experiment Video

Updated: Jun 8, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Extramedullary plasmacytoma are characterized by a 'myeloma-like' immunophenotype and genotype and occult bone marrow

Maayke Boll, Elizabeth Parkins, Sheila J M O'Connor

    British Journal of Haematology
    |October 1, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
    05:32

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

    Published on: January 7, 2019

    Related Experiment Videos

    Last Updated: Jun 8, 2026

    Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
    07:53

    Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

    Published on: April 15, 2022

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
    05:32

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

    Published on: January 7, 2019

    Related Concept Videos

    Induced Pluripotent Stem Cells01:06

    Induced Pluripotent Stem Cells

    Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
    Somatic cells are...
    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

    Articles linked to this work by shared authors, journal, and citation graph.

    Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

    The Lancet. Oncology·2026

    Deep phenotyping ILCs and T cells: A comparative analysis protocol for conventional and spectral flow cytometry.

    STAR protocols·2026

    Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

    Blood advances·2026

    Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.

    Blood advances·2025

    Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.

    Blood·2025

    Report of Consensus Panel 4 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphoma.

    Seminars in hematology·2025

    Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.

    British journal of haematology·2026

    Carrying a crisis: The risk of a painful sickle cell crisis during pregnancy.

    British journal of haematology·2026

    Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

    British journal of haematology·2026

    Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification-Insights from chromosome count and cytogenetic abnormalities.

    British journal of haematology·2026

    A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.

    British journal of haematology·2026

    Interplay between fibroblast growth factor 9 (FGF9) and CD44 underlies 46,XY disorders of sex development in Kruppel-like factor 1 (KLF-1)-E325K-associated congenital dyserythropoietic anaemia (CDA-IV).

    British journal of haematology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us